BRAF-Mutant Tumors Sensitive to Mek Inhibitors, Says Sloan-Kettering Group; NCI-60 Data Confirms | GenomeWeb

A new class of drugs may join the ranks of personalized therapies.

Tumors with a mutated BRAF gene are especially sensitive to drugs that inhibit the Mek protein, according to research led by Memorial Sloan-Kettering Cancer Center scientists and published this week in an advance online issue of Nature. Both BRAF and MEK are part of the same biological pathway as the pharmacogenomic favorite, EGFR.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.